Medicalgorithmics, a leader in cardiac diagnostics software listed on the Warsaw Stock Exchange, has presented its estimated revenues for the third quarter, which amounted to nearly PLN 7.2 million, up 38% year-on-year. The medtech company is intensifying its period of dynamic growth, driven by record interest and sales of software based on innovative AI algorithms, mainly in the United States, where revenues are growing by as much as 76%. Since the beginning of 2025, Medicalgorithmics has already signed 17 agreements with new customers, including three on the US market. The new agreements, including one with one of the largest US IDTFs, are already translating into results, and the company anticipates further growth in revenues from their implementation in the fourth quarter and subsequent periods.
– The dynamics observed in the third quarter show what a turning point we are at. All new contracts we have signed concern proprietary algorithms or software developed by Medicalgorithmics, and in the United States, 100% of generated revenue already comes from software sales. What is more, during the period in question, we integrated with one of the largest IDTFs in the US, which then doubled the number of tests performed thanks to an upgrade. We are continuing our development and working to ensure that such dynamics are announced regularly, starting in the fourth quarter of this year – says Dr. Kris Siemionow, CEO of Medicalgorithmics.
According to estimates as of September 30 this year, the Group’s revenues in the third quarter of 2025 amounted to approximately PLN 7.17 million, which represents a 38% increase year-on-year. Sales revenues in the US increased by as much as 76% year-on-year, to PLN 2.2 million. The estimates also indicate the number of sessions, which grew at a rate of +34% y/y and amounted to almost 97k.
– The integrations we are working on, the implementation of a contract with one of the largest IDTFs in the US, and new agreements will also result in an increase in the number of sessions performed using our solutions. In 2024, we doubled their number, and this year the growth rate should also be above average – adds Dr. Kris Siemionow, CEO of Medicalgorithmics.
Since the beginning of 2025, the medtech company listed on the Warsaw Stock Exchange has been growing dynamically, acquiring new customers and activating existing ones, resulting in a record number of contracts concluded (17 – more than in the whole of 2024). In addition to the aforementioned American users of Medicalgorithmics technology, new contracts also include: an agreement with the European IDTF, an agreement with an American deep-tech company specializing in the integration of advanced materials, sensors, and artificial intelligence, and the first two commercial agreements for VCAST – on the Turkish market and the strategic Scandinavian market.